These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37914618)

  • 21. Assessment of late-term progression of cardiac allograft vasculopathy in patients with orthotopic heart transplantation using quantitative cardiac
    Shrestha UM; Sciammarella M; Pampaloni MH; Botvinick EH; Gullberg GT; DeMarco T; Seo Y
    Int J Cardiovasc Imaging; 2021 Apr; 37(4):1461-1472. PubMed ID: 33123937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Endothelin-1 With Accelerated Cardiac Allograft Vasculopathy and Late Mortality Following Heart Transplantation.
    Parikh RV; Khush K; Pargaonkar VS; Luikart H; Grimm D; Yu M; Okada K; Honda Y; Yeung AC; Valantine H; Fearon WF
    J Card Fail; 2019 Feb; 25(2):97-104. PubMed ID: 30543947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network.
    Fluschnik N; Geelhoed B; Becher PM; Schrage B; Brunner FJ; Knappe D; Bernhardt AM; Blankenberg S; Kobashigawa J; Reichenspurner H; Schnabel RB; Magnussen C
    Int J Cardiol; 2021 May; 331():57-62. PubMed ID: 33571561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive Physiologic Assessment of Cardiac Allograft Vasculopathy Is Prognostic for Post-Transplant Events.
    Clerkin KJ; Topkara VK; Farr MA; Jain R; Colombo PC; Restaino S; Sayer G; Castillo M; Lam EY; Chernovolenko M; Yuzefpolskaya M; DeFilippis E; Latif F; Zorn E; Takeda K; Johnson LL; Uriel N; Einstein AJ
    J Am Coll Cardiol; 2022 Oct; 80(17):1617-1628. PubMed ID: 36265957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
    Asleh R; Briasoulis A; Smith B; Lopez C; Alnsasra H; Pereira NL; Edwards BS; Clavell AL; Stulak JM; Locker C; Kremers WK; Daly RC; Lerman A; Kushwaha SS
    J Card Fail; 2021 May; 27(5):542-551. PubMed ID: 33962742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients.
    Szczurek W; Gąsior M; Skrzypek M; Szyguła-Jurkiewicz B
    Am J Transplant; 2020 Oct; 20(10):2857-2866. PubMed ID: 32378779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy.
    Raichlin ER; McConnell JP; Lerman A; Kremers WK; Edwards BS; Kushwaha SS; Clavell AL; Rodeheffer RJ; Frantz RP
    J Heart Lung Transplant; 2007 Aug; 26(8):826-33. PubMed ID: 17692787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients.
    Javaheri A; Molina M; Zamani P; Rodrigues A; Novak E; Chambers S; Stutman P; Maslanek W; Williams M; Lilly SM; Heeger P; Sayegh MH; Chandraker A; Briscoe DM; Daly KP; Starling R; Ikle D; Christie J; Rame JE; Goldberg LR; Billheimer J; Rader DJ
    J Heart Lung Transplant; 2016 Nov; 35(11):1295-1302. PubMed ID: 27498384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
    Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of Real-Time Myocardial Contrast Echocardiography to Detect Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Fine NM; Greenway SC; Mulvagh SL; Huang R; Maxon SA; Hepinstall MJ; Anderson JH; Johnson JN
    J Am Soc Echocardiogr; 2021 May; 34(5):503-510. PubMed ID: 33359634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Quantitative Flow Ratio in Predicting Future Cardiac Allograft Vasculopathy in Heart Transplant Recipients.
    Spitaleri G; Brugaletta S; Potena L; Mirabet S; González-Costello J; Zucchetti O; Masetti M; Asmarats L; Gual M; Nardi E; Di Girolamo D; Campo G; Farrero M
    Circ Cardiovasc Interv; 2022 May; 15(5):e011656. PubMed ID: 35580200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.
    Zanchin C; Yamaji K; Rogge C; Lesche D; Zanchin T; Ueki Y; Windecker S; Mohacsi P; Räber L; Sigurdardottir V
    PLoS One; 2018; 13(8):e0202950. PubMed ID: 30148864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods.
    Kransdorf EP; Loghmanpour NA; Kanwar MK; Temkit MH; Stehlik J
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy.
    Bravo PE; Bergmark BA; Vita T; Taqueti VR; Gupta A; Seidelmann S; Christensen TE; Osborne MT; Shah NR; Ghosh N; Hainer J; Bibbo CF; Harrington M; Costantino F; Mehra MR; Dorbala S; Blankstein R; Desai A; Stevenson L; Givertz MM; Di Carli MF
    Eur Heart J; 2018 Jan; 39(4):316-323. PubMed ID: 29236988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased fibrosis and microvessel disease in allograft endomyocardial biopsies of children with chronic graft failure due to cardiac allograft vasculopathy.
    Watanabe K; Husain N; Arzu JL; Wechsler JB; Arva NC
    Cardiovasc Pathol; 2023; 63():107509. PubMed ID: 36442702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of dual imaging stress echocardiography for the diagnosis of coronary allograft vasculopathy in heart transplant recipients.
    Pichel IÁ; Fernández Cimadevilla OC; de la Hera Galarza JM; Pasanisi E; Ruiz JMG; Molina BD; Rodriguez JLL; Sicari R; Fernández MM
    Int J Cardiol; 2019 Dec; 296():109-112. PubMed ID: 31324395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial Perfusion Reserve and Strain-Encoded CMR for Evaluation of Cardiac Allograft Microvasculopathy.
    Erbel C; Mukhammadaminova N; Gleissner CA; Osman NF; Hofmann NP; Steuer C; Akhavanpoor M; Wangler S; Celik S; Doesch AO; Voss A; Buss SJ; Schnabel PA; Katus HA; Korosoglou G
    JACC Cardiovasc Imaging; 2016 Mar; 9(3):255-66. PubMed ID: 26965729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive aortic pulse pressure is linked to cardiac allograft vasculopathy after heart transplantation.
    Park HW; Ozcan I; Toya T; Ahmad A; Kanaji Y; Kushwaha SS; Lerman LO; Lerman A
    Int J Cardiol; 2023 Jan; 370():167-174. PubMed ID: 36346255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.